SINGAPORE, August 29, 2024 – PairX Bio has been selected by Johnson & Johnson Innovation - JLABS Singapore as its Navigator Awardee. This prestigious honor grants us a one-year membership at JLABS Singapore, providing access to JLABS’ extensive global network of industry experts and resources.
JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across the spectrum of healthcare. This membership will help us pioneer the development of next-generation cancer-selective biologics, offering hope to a wider range of people living with difficult-to-treat cancers.
“We are honored to be selected as the Navigator Awardee by Johnson & Johnson Innovation - JLABS Singapore and to join its vibrant community of innovators,” said David Epstein, President and CEO of PairX Bio. “With this membership, PairX Bio is poised to make significant strides in our research and development initiatives instrumental to unleashing the clinical impact of selective biologics for patients living with difficult-to-treat cancers.”
댓글